• Filing Date: 2020-11-03
  • Form Type: 10-Q
  • Description: Quarterly report
v3.20.2
Condensed Consolidated Statements Of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
NET REVENUE $ 12,473 $ 12,850 $ 37,046 $ 36,595
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1,537) (1,579) (4,949) (4,353)
GROSS PROFIT 10,936 11,271 32,097 32,242
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 2,469 2,761 7,162 8,322
GENERAL AND ADMINISTRATIVE EXPENSES 2,619 3,121 8,775 10,189
SALES AND MARKETING EXPENSES 4,764 6,437 14,818 18,458
DEPRECIATION AND AMORTIZATION 677 668 2,016 1,974
OPERATING EXPENSES 10,529 12,987 32,771 38,943
NET INCOME (LOSS) FROM OPERATIONS 407 (1,716) (674) (6,701)
INTEREST EXPENSE AND OTHER (1,285) (1,232) (3,928) (3,696)
UNREALIZED FOREIGN CURRENCY GAIN (LOSS), NET 267 (115) 295 (135)
NET LOSS BEFORE TAXES (611) (3,063) (4,307) (10,532)
PROVISION FOR TAXES (7) (77) (55) (409)
NET LOSS $ (618) $ (3,140) $ (4,362) $ (10,941)
NET (LOSS) INCOME PER COMMON SHARE — Basic and diluted (in dollars per share) $ (0.12) $ (0.66) $ (0.87) $ (2.31)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING — Basic and diluted (in shares) 5,068,701 4,733,484 5,026,905 4,727,472